ROARABLE
FREE $100K
My Trading Account β†’
β–Ύ
Trading Profile Active
Active Trader
Verified Trader
⚑ My $100K Trading Account β†’ β˜… My Saved Watchlist β†’
🟒 My $100K Account β†’ Today Screener Big Ideas Track Record πŸ’° $100K Arena 🎲 Predictions πŸ›οΈ Insiders 8 Analysts
Stock Ratings / Health Care / GOSS / insiders
XBIT (32) RNXT (29) BOLD (46) HRTX (34) ⌘ Pro Terminal β†’

Gossamer Bio Inc. (GOSS) Insider, 13F Hedge Fund & Politician Buy/Sell Thermometer

$9.45 -8.96% NASDAQ β€’ Live Quote vs Prior Daily Close (Synced Snapshot) EXT / AFTER-HRS: $9.28

Gossamer Bio Inc. (GOSS) carries a Roarable Rating of E (Strong Sell) with 28/100 RQD Confidence due to weak cash-flow efficiency and sensitivity to current interest rates. Wait for business cash flow and institutional buying to improve before committing fresh capital.

ROARABLE E β€’ RED ALERT Cap $57.8M
πŸ“€ Share Live RQD Speedometer Card: 𝕏 Post Reddit StockTwits ⬇ Live SVG Card
⚑ INSTANT AI QUANT PREVIEW β€’ $0 FREE TIER Click Any Pre-Computed AI Quant Specialist Briefing on GOSS Below β€” or Connect Your Own ChatGPT / Claude
πŸ€– Mara Quenwick β€’ AI Quant Lead (Click for Instant Brief) Is GOSS stock a Buy, Hold, or Sell right now according to Roarable's RQD model?
β–Ό

As of 2026-11-03, Gossamer Bio Inc. (NASDAQ: GOSS) is rated E (Strong Sell / SELL) by Roarable's 5-pillar RQD engine with a composite confidence score of 28/100 at a spot price of $9.45 (-8.96% 1D, market cap $57.8M). Pillar breakdown: Fundamental Cash Engine 6/20, Institutional 13F & Options Flow 5/20, SEC Balance-Sheet Forensics 8/20, FRED Macro Regime Fit 6/20, and Executive Insider Alignment 3/20. Across 1015 tracked Health Care issuers, GOSS ranks #865 in composite RQD confidence.

βœ“ Pre-computed one-to-many AI Quant brief
πŸ€– Ellis Vennor β€’ AI Peer & Flow Quant (Click for Instant Brief) How does GOSS compare to XBIT and RNXT in the Health Care sector?
β–Ό

Within the Health Care sector (Biotechnology: Pharmaceutical Preparations), GOSS carries a Roarable E (28/100 RQD), trailing P/E of N/A, gross margin of β€”, and ROIC of -35.0%. By comparison, XBIT (XBiotech Inc.) holds a E grade (32/100 RQD, P/E N/A, ROIC -35.0%, cap $58.5M) and RNXT (RenovoRx Inc.) posts a E grade (29/100 RQD, P/E N/A, ROIC -35.0%, cap $56.9M). Among the 5-stock peer group, GOSS leads on earnings multiple (N/A) while GOSS leads on capital efficiency (-35.0% ROIC).

βœ“ Pre-computed one-to-many AI Quant brief
πŸ€– Gideon Ashmere β€’ AI SEC 10-K Forensics (Click for Instant Brief) What are the biggest fundamental strengths and SEC risk factors for GOSS?
β–Ό

Per GOSS's SEC EDGAR XBRL 10-K filing (FY2025, filed 2025-12-31, CIK 0001728117), Gossamer Bio Inc. generated $48.5M in revenue (-57.7% YoY), -$170.4M in net income, and -$171.3M in free cash flow against $172.2M in total assets and $0 in total debt. Key quantitative strengths: Established market leader in Health Care with deep daily trading liquidity. Primary risk factors monitored: Company executives have done more routine share selling than personal cash buying lately. Institutional options positioning shows a 50% call / 50% put premium split.

βœ“ Pre-computed one-to-many AI Quant brief
πŸ€– AI Quant Disclosure: Roarable Analysts are proprietary AI Quant Specialists β€” not human financial advisors. Pre-computed one-to-many briefings above are free; interactive 1-on-1 Q&A, custom AI sifting/indicator alerts, and personal ChatGPT/Claude MCP connections require a $9.95/mo Pro account (currently waitlist-only).
INTERACTIVE SCENARIO DECK:
πŸ›‘οΈ Portfolio Crash X-Ray
EXT / AFTER-HRS: $9.28 (-1.80%)🧬 Dilution Drag (+1.28% YoY Shares)βš™οΈ Cash Engine: 6/20 (E) β€’ 0% FCF Margin
Verify 90D Bucket Audit β†’
πŸ“Š Historical Track Record Warning: Scores below 50 (28/100 Β· E) historically underperformed SPY in 71% of rolling 90-day windows (-10.0% avg 90D alpha vs SPY β€’ 29.0% hit rate).
Audit Bucket Track Record β†’
RQD QUANT TACHOMETERRED ALERT β€’ E
025507510028
3-of-3 Quant Analysts Bearish Warning
Cash
SEC
Whale

Impersonal quantitative research (0–100 RQD rubric) β€” not individualized investment advice. Past performance does not guarantee future results. Full Disclaimer

5-PILLAR RQD RADARRw E Β· Rk D-
Cash (6)Whales (5)SEC (8)Macro (6)CEO (3)
Each axis scored 0–20
12M PRICE TARGET CONE-13.5% Base Target
$325 Bull$8 Base$6 Bear
πŸ“¬ FREE GOSS RATING-CHANGE & BRIEFING ALERTSManage / Unsubscribe
WHALE OPTIONS SNAPSHOT: β€” (No Active Options Snapshot on file for GOSS)Realized 20D OHLCV Swing Band: Β±12.5%
Deterministic 5-Pillar Attribution (28/100 Composite)
πŸ” WHY GOSS SCORES 28/100 (E) β€” TOP 3 DRIVERS2 Bullish Pillars + #1 Risk Drag
β–² #1 Bullish Driver: SEC 10-K Forensic Risk+8/20 pts (29% of score)

Altman Z-Score 3.80 (FORTRESS SAFE (>3.0)) β€’ Piotroski F-Score 1/9

β–² #2 Bullish Driver: Cash Engine Quality+6/20 pts (21% of score)

SEC XBRL FY 2025 (10-K): 0% FCF Margin ($0 FCF) & 52% Gross Margin

β–Ό #1 Drag / Risk Factor: Insider Conviction & Share Dilution4/20 pts (-16 pt drag)

Dilution Drag (+1.28% YoY Shares) & executive Form 4 sales trim 16 pts from alignment

πŸ“ˆ PAST 4 QUARTERS RQD vs SUBSEQUENT RETURNQ1 β†’ Q2 β†’ Q3 β†’ Current
Q1 (-3Q)
36
Grade E$9.76-1.8% Next Q
Q2 (-2Q)
33
Grade E$9.58+2% Next Q
Q3 (-1Q)
31
Grade E$9.77-3.3% Next Q
Current
28
Grade E$9.45-10% Hist 90D Ξ±
Trajectory: E (36) β†’ E (28)Full Audit β†’
βš”οΈ ADVERSARIAL OPPOSING CASE & FORENSIC KILL-SWITCH (WHY THE BULL/BEAR THESIS COULD FAIL)CONTRARIAN TURNAROUND & SHORT-SQUEEZE DOSSIER

βš”οΈ Adversarial Opposing Case: What Could Spark a GOSS Turnaround Squeeze

Gideon Ashmere Forensic Desk β†’

While GOSS currently carries a cautious 28/100 (E) rating due to Insider Conviction & Share Dilution (4/20), shorts face asymmetric squeeze risk if free cash flow inflects or management executes accretive buybacks.

πŸš€ Contrarian Squeeze Trigger #1

Established market leader in Health Care with deep daily trading liquidity.

πŸš€ Contrarian Squeeze Trigger #2

Options & Short-Covering Gamma: Reclaiming the 50-day SMA ($11.13) and Max Pain ($9.92) forces dealer call-delta covering toward $325.08.

πŸš€ Contrarian Squeeze Trigger #3

Forensic Repair Trigger: Halting share dilution (Dilution Drag (+1.28% YoY Shares)) or retiring high-cost debt immediately upgrades the SEC 10-K Forensic pillar.

🎲 LIVE PREDICTION MARKET ODDS TIED TO $GOSSβ€’ $2.4M Crowd Pool β€’ Kalshi / Polymarket Composite
Contract: β€œGOSS Beats Next Quarter EPS Consensus (Dec 30, 2026) & Holds Above 200D SMA”
YES 28%NO 72%Trade / Inspect Odds β†’
SEC FORM 4 Γ— 13F HEDGE FUNDS Γ— CONGRESSIONAL STOCK ACT

GOSS Smart-Money Thermometer: NET EXECUTIVE TRIMMING / PROFIT-TAKING

Explore All 13F & Congress Whales β†’
β–² Disclosed Buys: 0 ($0)β–Ό Disclosed Sales: 0 ($0)

Wide-Open SEC Form 4, 13F & Congressional Disclosure Ledger (GOSS)

No recent open-market Form 4 cluster sales or emergency dumps flagged on GOSS. Visit the Global 13F & Congressional Whale Ledger for cross-market smart-money filings.

ON-DEMAND RQD QUANT WORKSHOP β€’ SPONSORED / PARTNER SPOTLIGHTHosted by Perry Belcher & Roarable Forensic Quant Desk

Red-Light Warning Desk: Spotting SEC Cash-Flow & Dilution Risks Before Downgrades (Featuring GOSS)

  • βœ“Walkthrough of GOSS's RQD Radar, SEC cash-conversion gap & downside invalidation levels
  • βœ“3 asymmetric Bear/Hedge frameworks when 10-year Treasury yields stay elevated
  • βœ“Includes nightly RQD rating-change & forensic signal email alerts on your tracked stocks
RQD INSIDER CLUB WAITLIST$49/YR PLANNED
Want Custom AI PineScript / Python Indicators & Priority Rating-Change Alerts?
Join Founding VIP Waitlist (No Card Required) β†’$100K Arena
GOSS // CANDLESTICK & AUTO-TRENDLINE WORKSTATION6M: -64.84%⚑ TESTING RESISTANCE
2026-11-04O $10.38H $10.38L $9.45C $9.45VOL 190.8K
RES: $10.78SUP: $7.66SMA50: $11.13SMA200: $39.29
$175.0$129.8$84.65$39.46$-5.73RES $10.78SUP $7.66$9.452026-05-052026-06-182026-08-052026-09-182026-11-04
PRIMARY-SOURCE FORENSICS, SECOND-ORDER LINKS & AI ANALYST DESK

GOSS Dilution Monitor, Expectations Hurdle, Butterfly Connections & Policy Exposure

πŸ¦‹ GOSS Butterfly Map β†’ + Track GOSS β†’
Share Count & Dilution Monitor

Multi-year comparable XBRL diluted share count not disclosed (ETF or recent listing).

Reverse-DCF Expectations Hurdle
8.0%/yr Implied 5Y Growth

vs. -57.7% actual YoY revenue growth (assuming 9.25% cost of equity & 16.5x terminal multiple).

Ellis Vennor Setup Ledger

No active Ellis Vennor swing setup published on GOSS today. View full Setup Ledger β†’

πŸ¦‹ Documented & Second-Order Butterfly Connections Open Graph β†’

No direct multi-tier Butterfly edges indexed yet for GOSS. Explore sector supply chains on /butterfly.

AI Analyst Theses, Washington Policy & Company Video
🎬 No recent verified company-specific video clip queued for GOSS today (we never pad ticker pages with unrelated generic clips). Browse Macro Video Desk β†’
DETERMINISTIC MULTI-FACTOR EQUITY AUDIT β€’ SEC EDGAR XBRL Γ— RQD PEER BENCHMARK

πŸ“Š Quantitative Sector Peer Comparison, SEC Filing Delta & Investment FAQ (GOSS)

Health Care Rank #865 of 1015 βš”οΈ XBIT vs GOSS Full Matrix β†’

1. Head-to-Head Health Care Peer Comparison (GOSS vs. XBIT, RNXT, BOLD, HRTX)

Industry: Biotechnology: Pharmaceutical Preparations (489 Tracked Issuers)

Across 1015 tracked Health Care securities in the Roarable RQD universe, Gossamer Bio Inc. (GOSS) ranks #865 by composite RQD confidence (28/100, grade E) and #718 by equity capitalization ($57.8M). Within this direct 5-issuer industry benchmark cohort, GOSS leads on earnings valuation at N/A trailing P/E, while GOSS leads on capital efficiency and profitability with -35.0% ROIC and β€” gross margin. BOLD currently holds the highest overall quantitative score in the immediate peer group at 46/100 (D) compared with GOSS at 28/100 (E).

Ticker / Company Roarable Grade RQD Score Trailing P/E Gross Margin ROIC 1D Change Market Cap Head-to-Head
GOSS ACTIVE
Gossamer Bio Inc.
E 28/100 β€” β€” -35.0% -8.96% $57.8M Benchmark Subject
XBIT
XBiotech Inc.
E 32/100 β€” β€” -35.0% +2.13% $58.5M /xbit-vs-goss β†’
RNXT
RenovoRx Inc.
E 29/100 β€” 70.9% -35.0% -5.26% $56.9M /rnxt-vs-goss β†’
BOLD
Boundless Bio Inc.
D 46/100 β€” β€” -35.0% -1.22% $56.4M /bold-vs-goss β†’
HRTX
Heron Therapeutics Inc.
E 34/100 β€” 73.3% -35.0% +6.27% $56.0M /hrtx-vs-goss β†’

2. Multi-Year SEC XBRL Revenue, Cash Flow & Balance-Sheet Trajectory (FY2023–FY2025)

SEC EDGAR 10-K β€’ FILED 2025-12-31 β€’ CIK 0001728117 β†—

In its most recent audited fiscal period (FY2025, filed 2025-12-31), Gossamer Bio Inc. (GOSS) reported GAAP revenue of $48.5M (-57.7% vs. FY2024 revenue of $114.7M , and -90.6% cumulative change since FY2023) , GAAP net income of -$170.4M, operating cash flow of -$171.3M, and free cash flow of -$171.3M (-4840.7% YoY). On the balance sheet, GOSS closed FY2025 with $172.2M in total assets against $0 in total debt (Altman Z-Score: N/A, Piotroski F-Score: 1/9).

Fiscal Period Filing Date Revenue Net Income Operating Cash Flow Free Cash Flow Total Assets Total Debt
FY2025 (FY) 2025-12-31 $48.5M -$170.4M -$171.3M -$171.3M $172.2M β€”
FY2024 (FY) 2024-12-31 $114.7M -$56.5M -$3.5M -$3.5M $315.3M $0
FY2023 (FY) 2023-12-31 $514.5M -$179.8M -$159.2M -$159.2M β€” β€”

3. GOSS Data-Verified Investor FAQ (RQD Rating, Sector Peers, SEC Forensics & Technicals)

βœ“ SCHEMA.ORG FAQPAGE JSON-LD ENABLED

Is GOSS stock a Buy, Hold, or Sell right now according to Roarable's RQD model?

As of 2026-11-03, Gossamer Bio Inc. (NASDAQ: GOSS) is rated E (Strong Sell / SELL) by Roarable's 5-pillar RQD engine with a composite confidence score of 28/100 at a spot price of $9.45 (-8.96% 1D, market cap $57.8M). Pillar breakdown: Fundamental Cash Engine 6/20, Institutional 13F & Options Flow 5/20, SEC Balance-Sheet Forensics 8/20, FRED Macro Regime Fit 6/20, and Executive Insider Alignment 3/20. Across 1015 tracked Health Care issuers, GOSS ranks #865 in composite RQD confidence.

How does GOSS compare to XBIT and RNXT in the Health Care sector?

Within the Health Care sector (Biotechnology: Pharmaceutical Preparations), GOSS carries a Roarable E (28/100 RQD), trailing P/E of N/A, gross margin of β€”, and ROIC of -35.0%. By comparison, XBIT (XBiotech Inc.) holds a E grade (32/100 RQD, P/E N/A, ROIC -35.0%, cap $58.5M) and RNXT (RenovoRx Inc.) posts a E grade (29/100 RQD, P/E N/A, ROIC -35.0%, cap $56.9M). Among the 5-stock peer group, GOSS leads on earnings multiple (N/A) while GOSS leads on capital efficiency (-35.0% ROIC).

What are the biggest fundamental strengths and SEC risk factors for GOSS?

Per GOSS's SEC EDGAR XBRL 10-K filing (FY2025, filed 2025-12-31, CIK 0001728117), Gossamer Bio Inc. generated $48.5M in revenue (-57.7% YoY), -$170.4M in net income, and -$171.3M in free cash flow against $172.2M in total assets and $0 in total debt. Key quantitative strengths: Established market leader in Health Care with deep daily trading liquidity. Primary risk factors monitored: Company executives have done more routine share selling than personal cash buying lately. Institutional options positioning shows a 50% call / 50% put premium split.

Where is GOSS trading relative to its 50-day, 200-day, and 52-week technical levels?

GOSS last traded at $9.45 (-8.96% on volume of 190,848 shares), positioning the stock -15.09% below its 50-day simple moving average ($11.13) and -75.95% below its 200-day simple moving average ($39.29). Across its 52-week range of $8.29 to $309.60, GOSS sits at the 0.4% percentile with a 14-day RSI of 43.5 (NEUTRAL RANGE) and an implied next-earnings move of Β±12.5% ($8.27 to $10.63).

Direct Sub-Reports: GOSS RQD Cockpit GOSS 12M Forecast GOSS Earnings & Move GOSS Dividends & DRIP GOSS Insiders & 13F GOSS Whale Options GOSS Profit Sankey GOSS News & Why
ROARABLE RATING BRIEF β€’ RQD 28/100 (E) βœ“ SEC XBRL & RQD VERIFIED

GOSS β€” Gossamer Bio Inc.: What the Facts Mean to a Prospective Investor

Methodology: RQD v6.2 Deterministic 5-Pillar & SEC XBRL Audit
Updated: 2025-12-31

1. Roarable Rating Brief: What This Means to a Prospective Investor

Gossamer Bio Inc. (GOSS) earns a live Roarable RQD composite score of 28/100, corresponding to a E letter grade (Roarable Strong Sell) at a spot price of $9.45 (-8.96% 1D, market capitalization $57.8M).

  • Fundamental Cash Engine (6/20): Anchored by return on invested capital (ROIC) of -35.0%, gross margin of β€”, operating margin of -60.0%, and free cash flow yield of β€”.
  • Whale 13F & Options Flow (5/20) + Insider Conviction (3/20): Tracks institutional 13F accumulation, CBOE options call/put positioning, and SEC Form 4 / Congressional PTR filings.
  • Macro Regime Fit (6/20) + Forensic Balance Sheet (8/20): Incorporates a 1.00x equity beta, Altman Z-Score of N/A, Piotroski F-Score of 1/9, and Debt/Equity of N/A.

2. Business Model, Unit Margins & SEC Financial Trajectory

Gossamer Bio Inc. (GOSS) is a NASDAQ-listed issuer in the Health Care sector, operating in the Biotechnology: Pharmaceutical Preparations industry. It has a market capitalization of $0.1B. FY 2025 revenue was $48.5M, down from $114.7M in FY 2024, and FY 2023 revenue was β€”.

In its latest audited SEC EDGAR 10-K filing for FY2025 (filed 2025-12-31), Gossamer Bio Inc. (GOSS) reported $48.5M in annual revenue (up from $114.7M in FY2024, -57.7% YoY) and -$170.4M in GAAP net income. Over the multi-year SEC filing window from FY2023 ($514.5M revenue, -$179.8M net income) through FY2025, GOSS scaled operating cash flow to -$171.3M and free cash flow to -$171.3M, backed by $172.2M in total assets against $0 in total debt.

3. Institutional Bull vs. Bear Thesis & Valuation Tradeoff

  • πŸ‚ Primary Bull Case (E β€’ RQD 28/100): Established market leader in Health Care with deep daily trading liquidity. Free cash flow yield of β€” and institutional whale pillar of 5/20. With Fundamental Cash Engine at 6/20 and Institutional Whale Flow at 5/20, sustained execution supports upside toward the upper end of the $8.29 – $309.60 52-week range.
  • 🐻 Primary Bear Case & Valuation Risk: Company executives have done more routine share selling than personal cash buying lately. Investors must weigh current valuation against -60.0% operating margins and a 1.00x macro beta.

4. 2nd-Order Butterfly Ripples & Key Questions to Watch

The graph therefore does not identify upstream suppliers, downstream customers, or sector correlations for GOSS. Second-order bottlenecks cannot be mapped from the source data. The only sector context is the classification in the profile: Health Care, Biotechnology: Pharmaceutical Preparations.

  • Key Question #1: Can GOSS sustain or expand its -60.0% operating margin and -35.0% ROIC against Biotechnology: Pharmaceutical Preparations peers over the next 4 quarters?
  • Key Question #2: Following FY2025 revenue of $48.5M and free cash flow of -$171.3M, how will capital allocation balance growth reinvestment against $0 in total debt?
  • Key Question #3: How sensitive is GOSS's equity valuation to Health Care capital spending cycles and macro interest-rate shifts (Beta 1.00x)?

GOSS Live News Feed, Press Releases & Catalyst Wire

Real-time company headlines, analyst actions, and sector developments for Gossamer Bio Inc. (GOSS) β€’ Click "Debate This Headline" to argue it in the Roar Pit below

πŸ’¬ Jump to GOSS Debate Forum (3) ↓
πŸ”₯ THE ROAR PIT β€’ LIVE COMMUNITY DEBATE 3 Active Posts & Replies

GOSS Bull vs. Bear Conversation Board β€” What's Your Call at $9.45?

πŸ‚ 67% BULLISH CONVICTION COMMUNITY TUG-OF-WAR ON GOSS 🐻 33% BEARISH CONVICTION
1. Pick Your Side on GOSS:
πŸ’‘ Tip: Back up your call with a price target or RQD metric to get upvoted to the top.
TA TapeReader_Pro RQD DEBATE OPENER β€’ Price Action & Volume Trader πŸ‚ BULLISH 🎯 Target: $13.70 (+32.0%)
πŸ“Œ Pinned Debate

The stock trades at $10.38 with a $65.4M market cap and a 1.0 beta, and reported revenue in FY 2025 was still $48.5M with $37.7M in cas

Long GOSS at $10.38 targeting $13.70. The stock trades at $10.38 with a $65.4M market cap and a 1.0 beta, and reported revenue in FY 2025 was still $48.5M with $37.7M in cash on hand.. Institutional whale score is 5/20 and the risk/reward vs. the $8.29 52-week low is skewed heavily in favor of bulls.

VolSurface_Trader πŸ‚ BULL

Both sides have a point here β€” GOSS's 8/20 balance sheet score keeps downside contained, so the real swing factor next earnings call is backlog and FCF conversion.

ME MeanReversion_88 RQD DEBATE OPENER β€’ Quantitative Statistical Arb 🐻 BEARISH 🎯 Target: $8.41 (-19.0%)
Spot @ $10.38

Free cash flow was -$171.3M in FY 2025 against $48.5M of revenue, ROIC is -35%, and the RQD rating is an E at 33 with a Piotroski F-Sco

Here is the bear case nobody on the bull side wants to address on GOSS: Free cash flow was -$171.3M in FY 2025 against $48.5M of revenue, ROIC is -35%, and the RQD rating is an E at 33 with a Piotroski F-Score of 1/9.. At current EV/EBITDA multiples, even a small guidance miss in Biotechnology: Pharmaceutical Preparations triggers a 12-15% air pocket.

LIVE TAPE